DrugsNews.net

Drugs Xagena

Xagena Mappa
Xagena Newsletter
OncologiaMedica.net
Reumabase.it

The European Commission has granted Marketing Authorisation for Dovato ( Dolutegravir / Lamivudine ) for the treatment of HIV-1 infection in adults and adolescents above 12 years of age weighing at le ...


The FDA ( U.S. Food and Drug Administration ) has approved Dupixent ( Dupilumab ) for use with other medicines to treat chronic rhinosinusitis with nasal polyposis ( CRSwNP ) in adults whose disease i ...


The European Commission has approved Talzenna ( Talazoparib ), an oral poly (ADP-ribose) polymerase ( PARP ) inhibitor, as monotherapy for the treatment of adult patients with germline breast cancer s ...


The European Commission ( EC ) has approved Lynparza ( Olaparib ) as a 1st-line maintenance treatment for women with BRCA-mutated advanced ovarian cancer. The licensed indication is as a maintenanc ...


The European Commission ( EC ) has granted conditional marketing authorization for Lorviqua ( Lorlatinib, available in the U.S., Canada and Japan under the brand name Lorbrena ), as a monotherapy for ...


The European Commission has approved Dupixent ( Dupilumab ) for use in adults and adolescents 12 years and older as an addon maintenance treatment for severe asthma with type 2 inflammation characteri ...


The U.S. Food and Drug Administration ( FDA ) has approved Jakafi ( Ruxolitinib ) for the treatment of steroid-refractory acute GVHD in adult and pediatric patients 12 years and older. Jakafi is the f ...


The FDA ( U.S. Food and Drug Administration ) has approved Piqray ( Alpelisib ) tablets, to be used in combination with the FDA-approved endocrine therapy Fulvestrant, to treat postmenopausal women, a ...


The US Food and Drug Administration ( FDA ) has approved Bavencio ( Avelumab ) in combination with Inlyta ( Axitinib ) for the first-line treatment of patients with advanced renal cell carcinoma ( RCC ...


The U.S. Food and Drug Administration ( FDA ) has approved Venclexta ( Venetoclax ) in combination with Obinutuzumab ( Gazyva ) for previously untreated patients with chronic lymphocytic leukemia ( CL ...


The U.S. Food and Drug Administration ( FDA ) has approved Cyramza ( Ramucirumab injection, 10 mg/mL solution ), as a single agent, for the treatment of patients with hepatocellular carcinoma ( HCC ) ...


The FDA ( U.S. Food and Drug Administration ) has approved Benlysta ( Belimumab ) intravenous ( IV ) infusion for treatment of children with systemic lupus erythematosus ( SLE ), a serious chronic dis ...


The European Commission ( EC ) has approved Skyrizi ( Risankizumab ) for the treatment of moderate to severe plaque psoriasis in adult patients who are candidates for systemic therapy. Skyrizi ( 150 m ...


The European Commission has granted marketing authorization for Zynquista ( Sotagliflozin ), at once-daily doses of 200 mg and 400 mg, for use as an adjunct to Insulin therapy to improve glycemic cont ...


The FDA ( U.S. Food and Drug Administration ) has approved Praluent ( Alirocumab ) to reduce the risk of myocardial infarction, stroke, and unstable angina requiring hospitalization in adults with est ...


The FDA ( U.S. Food and Drug Administration ) has approved Dovato ( Dolutegravir and Lamivudine ), as a complete regimen for the treatment of human immunodeficiency virus type 1 ( HIV-1 ) infection in ...


The FDA ( U.S. Food and Drug Administration ) has granted accelerated approval to Balversa ( Erdafitinib ), a treatment for adult patients with locally advanced or metastatic bladder cancer that has a ...


The FDA ( U.S. Food and Drug Administration ) has approved Mayzent ( Siponimod ) tablets to treat adults with relapsing forms of multiple sclerosis, to include clinically isolated syndrome, relapsing- ...


The FDA ( U.S. Food and Drug Administration ) has extended the indication of Ibrance ( Palbociclib ) capsules in combination with specific endocrine therapies for hormone receptor-positive ( HR+ ), hu ...


The FDA ( U.S. Food and Drug Administration ) has approved Zulresso ( Brexanolone ) injection for intravenous ( IV ) use for the treatment of postpartum depression ( PPD ) in adult women. This is th ...


The European Commission ( EC ) has approved a new indication for Praluent ( Alirocumab ), to reduce cardiovascular ( CV ) risk in adults with established atherosclerotic CV disease ( ASCVD ) by loweri ...


The FDA ( U.S. Food and Drug Administration ) has approved Spravato ( Esketamine ) nasal spray, in conjunction with an oral antidepressant, for the treatment of depression in adults who have tried oth ...


The FDA ( U.S. Food and Drug Administration ) has approved Keytruda ( Pembrolizumab ), anti-PD-1 therapy, for the adjuvant treatment of patients with melanoma with involvement of lymph node(s) followi ...


The FDA ( U.S. Food and Drug Administration ) has granted approval for a new indication for Alimta ( Pemetrexed for injection ) in combination with Pembrolizumab ( Keytruda ) and Platinum chemotherapy ...


The FDA ( U.S. Food and Drug Administration ) has approved Cablivi ( Caplacizumab-yhdp ) in combination with plasma exchange and immunosuppression for the treatment of acquired thrombotic thrombocytop ...


The European Commission ( EC ) has approved Mylotarg ( Gemtuzumab ozogamicin ) in combination with Daunorubicin and Cytarabine for the treatment of patients age 15 years and above with previously untr ...


The U.S. Food and Drug Administration ( FDA ) has approved the 2-mg dose of Olumiant ( Baricitinib ), a once-daily oral medication for the treatment of adults with moderately-to-severely active rheuma ...


The Food and Drug Administration ( FDA ) has approved Lutathera ( Lutetium Lu 177 Dotatate ), a radiolabeled Somatostatin analog, for the treatment of Somatostatin receptor-positive gastroenteropancre ...


The Food and Drug Administration ( FDA ) has approved Hemlibra ( Emicizumab-kxwh; Emicizumab ) injection for prophylaxis to prevent or reduce the frequency of bleeding episodes in adult and pediatric ...


The U.S. Food and Drug Administration ( FDA ) has granted accelerated approval to Vitrakvi ( Larotrectinib ), a treatment for adult and pediatric patients whose cancers have a specific genetic feature ...


Menière's disease ( MD ) is an idiopathic pathological condition of the inner ear ( IE ) whose major symptoms are vertigo, fluctuating hearing loss, tinnitus, and fullness. These symptoms are most o ...


The FDA ( U.S. Food and Drug Administration ) has approved Elzonris ( Tagraxofusp-erzs; Tagraxofusp ) infusion for the treatment of blastic plasmacytoid dendritic cell neoplasm ( BPDCN ) in adults and ...


The FDA ( U.S. Food and Drug Administration ) has approved Xospata ( Gilteritinib ) tablets for the treatment of adult patients who have relapsed or refractory acute myeloid leukemia ( AML ) with a FL ...


The FDA ( U.S. Food and Drug Administration ) has approved the first drug, Oxervate ( Cenegermin ), for the treatment of neurotrophic keratitis, a rare disease affecting the cornea ( the clear layer t ...


The FDA ( Food and Drug Administration ) has approved Cemiplimab-rwlc ( Libtayo, Cemiplimab ) for patients with metastatic cutaneous squamous cell carcinoma ( CSCC ) or locally advanced CSCC who are n ...


FDA ( U.S. Food and Drug Administration ) has approved Inbrija ( Levodopa inhalation powder ) for intermittent treatment of OFF episodes in people with Parkinson’s disease treated with Carbidopa / Le ...


The FDA ( US Food and Drug Administration ) has approved Tecentriq ( Atezolizumab ) in combination with Avastin ( Bevacizumab ), Paclitaxel and Carboplatin ( chemotherapy ), for the initial ( first-li ...


The European Commission has approved Delstrigo and Pifeltro for the treatment of HIV-1 infection. Delstrigo is a new once-daily fixed-dose combination tablet of Doravirine ( 100 mg ), Lamivudine ( ...


The FDA ( U.S. Food and Drug Administration ) has approved Larotrectinib ( Vitrakvi ), the first oral TRK inhibitor. The approval is for the treatment of adult and pediatric patients with solid tumor ...


The FDA ( U.S. Food and Drug Administration ) has approved Keytruda ( Pembrolizumab ), an anti-PD-1 therapy, in combination with Carboplatin and either Paclitaxel or nab-Paclitaxel, for the first-line ...


The European Commission has approved Tafinlar ( Dabrafenib ) in combination with Mekinist ( Trametinib ) for the adjuvant treatment of stage III patients with BRAF V600 mutation-positive melanoma afte ...


The European Commission has approved Keytruda ( Pembrolizumab ), anti-PD-1 therapy, in combination with Pemetrexed ( Alimta ) and Platinum chemotherapy for the first-line treatment of metastatic nonsq ...


The European Commission ( EC ) has granted marketing authorization for Hulio, a biosimilar to Humira ( Adalimumab ), for all indications. The authorization follows the adoption of a positive opinio ...


The FDA ( U.S. Food and Drug Administration ) has approved Lumoxiti ( Moxetumomab pasudotox-tdfk ) injection for intravenous use for the treatment of adult patients with relapsed or refractory hairy c ...


The European Commission has approved Keytruda ( Pembrolizumab ), an anti-PD-1 therapy, in combination with Pemetrexed ( Alimta ) and Platinum chemotherapy for the first-line treatment of metastatic no ...


The FDA ( U.S. Food and Drug Administration ) has approved Tibsovo ( Ivosidenib ) tablets for the treatment of adult patients with relapsed or refractory acute myeloid leukemia ( AML ) who have a spec ...


The U.S. Food and Drug Administration ( FDA ) has approved Crysvita ( Burosumab-twza ), the first drug approved to treat adults and children ages 1 year and older with x-linked hypophosphatemia ( XLH ...


The FDA ( U.S. Food and Drug Administration ) has approved Poteligeo ( Mogamulizumab-kpkc ) injection for intravenous use for the treatment of adult patients with relapsed or refractory mycosis fungoi ...


The European Commission has granted marketing authorisation for Tagrisso ( Osimertinib ), a third-generation, irreversible EGFR-TKI, as monotherapy for the 1st-line treatment of adult patients with lo ...


Early data from two clinical trials have shown reduced survival with Keytruda ( Pembrolizumab ) and Tecentriq ( Atezolizumab ) when used as first-line treatments for urothelial cancer ( cancer of the ...